| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/17/2004 | US20040115767 Immunogenic cell surface proteins of helicobacter pylori |
| 06/17/2004 | US20040115762 Comprises nucleotide sequences coding enzymatic polypeptide associated biosynthesis of nystatin and treatment of bacterial, fungal and parasitic infections; immunosuppressant; antitumor agents |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115623 Identifying cmpounds which dramatically reduce herpes viral replicative capacity; viricides; enzyme inhibitors |
| 06/17/2004 | US20040115622 Mixture of peptides originating from a Nef protein and applications thereof |
| 06/17/2004 | US20040115619 Immunoglobulin which binds hepatitis c viral envelope proteins and prevents and treats viral diseases; immunotherapy; viricides |
| 06/17/2004 | US20040115615 Comprises amino acid sequences capable of inducing lymphadenopathy immune response without antagonizing cytotoxic lymphocytes; viricides and prevention of viral diseases |
| 06/17/2004 | US20040115272 Stability and dissolvability; for the therapy of an infectious disease |
| 06/17/2004 | US20040115255 Method and composition for solubilising a biologically active compound with low water solubility |
| 06/17/2004 | US20040115233 Composition for improving skin environment and clothes thereof |
| 06/17/2004 | US20040115212 Attenuated microorganism strains and their uses |
| 06/17/2004 | US20040115210 Imunogenic complex comprising ribosomes |
| 06/17/2004 | US20040115190 Methods and agents modulating upa/upar activity |
| 06/17/2004 | US20040115178 hydrophobic surface |
| 06/17/2004 | CA2509955A1 Formulations useful against hepatitis c virus infections |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507055A1 Treatment of prion-induced diseases by administration of anti-prion antibodies |
| 06/17/2004 | CA2507011A1 Phosphoantigens for regulating an immune response |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2481489A1 Cysteine protease inhibitor |
| 06/17/2004 | CA2453387A1 Compositions and methods related to nitrotyrosine-containing compounds as antigenic agents |
| 06/16/2004 | EP1428870A1 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation |
| 06/16/2004 | EP1428832A2 Peptide and O-glycan inhibitors of selectin mediated inflammation |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427849A2 Method of screening for drug hypersensitivity reaction |
| 06/16/2004 | EP1427846A2 Method of identifying glycosyl transferase binding compounds |
| 06/16/2004 | EP1427844A1 New assay for inhibitors of translocases |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427831A1 Yeast membrane protein expression system and its application in drug screening |
| 06/16/2004 | EP1427827A2 Synthetic hcv envelope proteins and their use for vaccination |
| 06/16/2004 | EP1427826A2 Hiv-gag codon-optimised dna vaccines |
| 06/16/2004 | EP1427817A1 Multiplication of viruses in a cell culture |
| 06/16/2004 | EP1427815A2 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
| 06/16/2004 | EP1427755A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 06/16/2004 | EP1427750A1 Modified transferrin fusion proteins |
| 06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 06/16/2004 | EP1427730A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| 06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
| 06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
| 06/16/2004 | EP1427717A1 Bioprecursors for percutaneous application |
| 06/16/2004 | EP1427711A1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427457A1 Medical devices containing rapamycin analogs |
| 06/16/2004 | EP1427450A2 Inhibition of rna function by delivery of inhibitors to animal cells |
| 06/16/2004 | EP1427445A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 06/16/2004 | EP1427442A2 Glycoconjugate vaccines for use in immune-compromised populations |
| 06/16/2004 | EP1427441A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 06/16/2004 | EP1427438A2 Inflammation modulatory compound comprising an endomorphin |
| 06/16/2004 | EP1427436A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 06/16/2004 | EP1427417A1 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents |
| 06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427402A1 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| 06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
| 06/16/2004 | EP1427395A1 Stabilization of active agents by formulation into nanoparticulate form |
| 06/16/2004 | EP1427349A2 Interleukin-12 as a veterinary vaccine adjuvant |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1265889B1 Medicaments against viral diseases |
| 06/16/2004 | EP1221950B1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 06/16/2004 | EP1214074B1 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/16/2004 | EP1200096B1 Tixocortol pivalate suspension, mouth-wash based thereon and packaging containing same |
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1173194B1 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation |
| 06/16/2004 | EP1071413B1 Topical formulations for the treatment of nail fungal diseases |
| 06/16/2004 | EP1064942B1 Sustained release preparation of a macrolide |
| 06/16/2004 | EP1058552B1 Steroid derived antibiotics |
| 06/16/2004 | EP0994889B1 Erythromycin a oxime solvates |
| 06/16/2004 | EP0986381B1 Use of diterpenes like hypoestoxides for the manufacture of a medicament for immunosuppression, anticancer and antiviral treatment |
| 06/16/2004 | EP0977725B1 New fatty acid derivatives |
| 06/16/2004 | EP0817635B1 Use of thiazepine, oxazepine and diazepine coumpounds for inhibiting hiv, herpesvirus and suppressing the immune system |
| 06/16/2004 | EP0789563B1 Hepatitis virus b and c vaccines |
| 06/16/2004 | EP0672133B1 TNF-alpha RIBOZYMES AND DEGRADATION RESISTANT mRNA DERIVATIVES LINKED TO TNF-alpha RIBOZYMES |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505635A Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| 06/16/2004 | CN1505634A Methods utilizing aryl thioimines in synthesis of erythromycin derivatives |
| 06/16/2004 | CN1505633A Anhydrous crystal of beta-lactam compound and method for producing the same |
| 06/16/2004 | CN1505629A Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505607A Peptide-deformylase inhibitors |
| 06/16/2004 | CN1505603A Substituted benzoic ac id derivatives exhibiting nf-ª—b inhibiting activity |
| 06/16/2004 | CN1505551A Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
| 06/16/2004 | CN1505537A Disease prevention by reactivation of the thymus |
| 06/16/2004 | CN1505524A Immunopotentiators |
| 06/16/2004 | CN1505522A Stimulation of thymus for vaccination development |
| 06/16/2004 | CN1505515A Oral pharmaceutical composition of cefpodoxime proxetil |
| 06/16/2004 | CN1505503A Method for preparing submicron particle suspensions |
| 06/16/2004 | CN1505478A Virucidal compositions |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504573A Confluent protein capable of self-cracking into polypeptide with antibiosis and reparation function |
| 06/16/2004 | CN1504482A Separation and purification process for acellular whooping cough antigen albumen |
| 06/16/2004 | CN1504237A Medicine composition containing alfa-interferon , adefovir and FTC |
| 06/16/2004 | CN1504236A Medicine composition containing alfa-interferon , lamivudine and adefovir |
| 06/16/2004 | CN1504228A Potherb tea powder capable of improving immunity and promoting immunity reestablishment of AIDS patients |
| 06/16/2004 | CN1504202A Pharmaceutical composition for cold |
| 06/16/2004 | CN1504199A Luminescent bio-element and preparation process |
| 06/16/2004 | CN1504196A Use of glycyrrhizin and its derivatives as mcp-1 production inhibitors |